Merck Vioxx Warning Letter Could Be Incentive For Large Cardio Safety Study
Executive Summary
Merck's Vioxx warning letter may serve as an additional incentive for the company to conduct a large cardiovascular safety study.
You may also be interested in...
Celebrex Heart Risk To Be Assessed By Cleveland Clinic In Pfizer-Funded Study
Pfizer's support for a massive study of Celebrex safety brings the drug maker together with researchers who have been urging the company to conduct additional trials; Pfizer approached Cleveland Clinic cardiovascular researchers about conducting the trial, which was announced Dec. 13
Celebrex Heart Risk To Be Assessed By Cleveland Clinic In Pfizer-Funded Study
Pfizer's support for a massive study of Celebrex safety brings the drug maker together with researchers who have been urging the company to conduct additional trials; Pfizer approached Cleveland Clinic cardiovascular researchers about conducting the trial, which was announced Dec. 13
Vioxx DTC Ads Consistent With “Learned Intermediary” Defense, Merck Says
The extensive direct-to-consumer advertising for Vioxx will not undercut Merck's ability to assert a "learned intermediary" defense against personal injury claims, the company told analysts Dec. 14